Canada markets closed

ImmunoPrecise Antibodies Ltd. (IPA.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
17.15+0.27 (+1.60%)
At close: 3:59PM EST
Currency in CAD

Valuation Measures

Market Cap (intraday) 5320.15M
Enterprise Value 3275.69M
Trailing P/E N/A
Forward P/E 1-25.22
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)19.17
Price/Book (mrq)9.25
Enterprise Value/Revenue 316.51
Enterprise Value/EBITDA 6-89.40

Trading Information

Stock Price History

Beta (5Y Monthly) 0.12
52-Week Change 3404.41%
S&P500 52-Week Change 323.92%
52 Week High 326.25
52 Week Low 30.81
50-Day Moving Average 319.25
200-Day Moving Average 313.31

Share Statistics

Avg Vol (3 month) 387k
Avg Vol (10 day) 391.46k
Shares Outstanding 518.67M
Float 15.03M
% Held by Insiders 19.78%
% Held by Institutions 10.01%
Shares Short (Feb. 11, 2021) 426.58k
Short Ratio (Feb. 11, 2021) 40.39
Short % of Float (Feb. 11, 2021) 4N/A
Short % of Shares Outstanding (Feb. 11, 2021) 40.14%
Shares Short (prior month Jan. 14, 2021) 416.89k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 390,000.00
Trailing Annual Dividend Yield 3533,175.39%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:5
Last Split Date 3Nov. 22, 2020

Financial Highlights

Fiscal Year

Fiscal Year Ends Apr. 29, 2020
Most Recent Quarter (mrq)Oct. 30, 2020

Profitability

Profit Margin -15.48%
Operating Margin (ttm)-26.87%

Management Effectiveness

Return on Assets (ttm)-8.00%
Return on Equity (ttm)-11.32%

Income Statement

Revenue (ttm)16.7M
Revenue Per Share (ttm)1.16
Quarterly Revenue Growth (yoy)50.30%
Gross Profit (ttm)7.95M
EBITDA -3.08M
Net Income Avi to Common (ttm)-2.58M
Diluted EPS (ttm)-0.18
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)16.84M
Total Cash Per Share (mrq)1
Total Debt (mrq)4.27M
Total Debt/Equity (mrq)13.73
Current Ratio (mrq)3.06
Book Value Per Share (mrq)1.85

Cash Flow Statement

Operating Cash Flow (ttm)1.27M
Levered Free Cash Flow (ttm)1.09M